| Autor: |
Yuba T; Internal Medicine, Social Insurance Kyoto Hospital., Nagata K, Shiotsu S, Okano A, Hatsuse M, Murakami S, Morihara K, Shimazaki C |
| Jazyk: |
japonština |
| Zdroj: |
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society [Nihon Kokyuki Gakkai Zasshi] 2010 Jan; Vol. 48 (1), pp. 81-5. |
| Abstrakt: |
Erlotinib is a newly developed molecular-targeting or molecular-targeted drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor. A adverse drug reactions including diarrhea, skin eruptions are considered mild. We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib. She received daily administration of erlotinib 150 mg as second-line chemotherapy. Her tumors decreased in size and pleural effusion disappeared, so we considered erlotinib effective. However after 3 months of treatment with erlotinib, the patient presented palpable purpuric lesions mostly located on her lower legs. We diagnosed Henoch-Schönlein purpura based on skin histological findings. Erlotinib was reduced but continued, with improvement of the eruptions. Henoch-Schönlein purpura is often accompanied by systemic manifestations, such as renal disease and arthritis, so more careful follow-up is warranted. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
